Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,106

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study

Open access
Postuma, Ronald B, Iranzo, Alex, Hu, Michele, Högl, Birgit, Boeve, Bradley F, Manni, Raffaele, Oertel, Wolfgang H, Arnulf, Isabelle, Ferini-Strambi, Luigi, Puligheddu, Monica, Antelmi, Elena, Cochen De Cock, Valerie, Arnaldi, Dario, Mollenhauer, Brit, Videnovic, Aleksandar, Sonka, Karel, Jung, Ki-Young, Kunz, Dieter, Dauvilliers, Yves, Provini, Federica, Lewis, Simon J, Buskova, Jitka, Pavlova, Milena, Heidbreder, Anna, Montplaisir, Jacques Y, Santamaria, Joan, Barber, Thomas R, Stefani, Ambra, St.Louis, Erik K, Terzaghi, Michele, Janzen, Annette, Leu-Semenescu, Smandra, Plazzi, Guiseppe, Nobili, Flavio, Sixel-Doering, Friederike, Dusek, Petr, Bes, Frederik, Cortelli, Pietro, Ehgoetz Martens, Kaylena, Gagnon, Jean-Francois, Gaig, Carles, Zucconi, Marco, Trenkwalder, Claudia, Gan-Or, Ziv, Lo, Christine, Rolinski, Michal, Mahlknecht, Philip, Holzknecht, Evi, Boeve, Angel R, Teigen, Luke N, Toscano, Gianpaolo, Mayer, Geert, Morbelli, Silvia, Dawson, Benjamin, Pelletier, Amelie·2019·Brain
DOI 10.1093/brain/awz030
Open this paper in CoChat — free account

Abstract

Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, and potentially intervene with neuroprotective therapy. For future neuroprotective trials, it is essential to accurately estimate phenoconversion rate and identify potential predictors of phenoconversion. This study assessed the neurodegenerative disease risk and predictors of neurodegeneration in a large multicentre cohort of iRBD. We combined prospective follow-up data from 24 centres of the International RBD Study Group. At baseline, patients with polysomnographically-confirmed iRBD without parkinsonism or dementia underwent sleep, motor, cognitive, autonomic and special sensory testing. Patients were then prospectively followed, during which risk of dementia and parkinsonsim were assessed. The risk of dementia and parkinsonism was estimated with Kaplan-Meier analysis. Predictors of phenoconversion were assessed with Cox proportional hazards analysis, adjusting for age, sex, and centre. Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis. Overall, 1280 patients were recruited. The average age was 66.3 ± 8.4 and 82.5% were male. Average follow-up was 4.6 years (range = 1-19 years). The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up. The rate of phenoconversion was significantly increased with abnormal quantitative motor testing [hazard ratio (HR) = 3.16], objective motor examination (HR = 3.03), olfactory deficit (HR = 2.62), mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2.11), an abnormal DAT scan (HR = 1.98), colour vision abnormalities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), and age (HR = 1.54). There was no significant predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic symptoms, depression, anxiety, or hyperechogenicity on substantia nigra ultrasound. Among predictive markers, only cognitive variables were different at baseline between those converting to primary dementia versus parkinsonism. Sample size estimates for definitive neuroprotective trials ranged from 142 to 366 patients per arm. This large multicentre study documents the high phenoconversion rate from iRBD to an overt neurodegenerative syndrome. Our findings provide estimates of the relative predictive value of prodromal markers, which can be used to stratify patients for neuroprotective trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awz030

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

Metadata

Authors
Postuma, R. B., Iranzo, A., Hu, M., Högl, B., Boeve, B. F., Manni, R., Oertel, W. H., Arnulf, I., Ferini-Strambi, L., Puligheddu, M., Antelmi, E., Cochen De Cock, V., Arnaldi, D., Mollenhauer, B., Videnovic, A., Sonka, K., Jung, K.-Y., Kunz, D., Dauvilliers, Y., Provini, F., Lewis, S. J., Buskova, J., Pavlova, M., Heidbreder, A., Montplaisir, J. Y., Santamaria, J., Barber, T. R., Stefani, A., St.Louis, E. K., Terzaghi, M., Janzen, A., Leu-Semenescu, S., Plazzi, G., Nobili, F., Sixel-Doering, F., Dusek, P., Bes, F., Cortelli, P., Ehgoetz Martens, K., Gagnon, J.-F., Gaig, C., Zucconi, M., Trenkwalder, C., Gan-Or, Z., Lo, C., Rolinski, M., Mahlknecht, P., Holzknecht, E., Boeve, A. R., Teigen, L. N., Toscano, G., Mayer, G., Morbelli, S., Dawson, B., & Pelletier, A.
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
2019-02-20
Volume
142
Issue
3
Pages
744-759
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
DOI
10.1093/brain/awz030
OpenAlex
W2917107887
Cited by
1,106
References
21
FWCI
64.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.